The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InVanda Pharmaceuticals has officially initiated the 'Thetis' clinical study to evaluate its drug NEREUS (tradipitant) for preventing vomiting in patients undergoing GLP-1 receptor agonist therapies. The trial specifically targets side effects associated with high-demand weight-loss and diabetes drugs such as semaglutide and tirzepatide. NEREUS recently received regulatory approval for preventing vomiting induced by motion sickness, providing a foundation for its expanded application. By addressing nausea and vomiting, Vanda aims to solve one of the primary reasons patients discontinue GLP-1 treatments. This strategic move allows the company to capitalize on the massive growth within the obesity medication market. Investors are closely watching the trial's progress, as successful clinical outcomes could significantly enhance Vanda's market position. The initiation of this trial marks a pivotal step in the company's clinical development pipeline.